Upload
others
View
6
Download
0
Embed Size (px)
Citation preview
Diagnosis and Management of Pancreatic Carcinoma - Best Practice, Pearls and Pitfalls
ZAHRA KASSAMSouthwest Regional Imaging Lead, Cancer Care Ontario
Assistant Professor of Medical Imaging and OncologySchulich School of Medicine, Western University
What the Radiologist Needs to Know in 2016
Objectives
Review 2014 SAR/APA recommendations for Pancreatic Adenocarcinoma (PAC) on CT - protocol,
staging, and reporting guidelines
Discuss results of LHIN-2 Retrospective Review with emphasis on importance of multidisciplinary
discussion
Review approaches for staging of suspected PAC that is not clearly biopsy-proven.
Pancreatic Adenocarcinoma –
Biology, Anatomy and CT Staging
Pancreatic carcinoma is a lethal disease -the only beneficial Rx is surgery with
negative margins (R0)
Despite “successful” surgery, virtually all patients will die from their disease
Biology is everything
Whipple ResectionModern Surgical Results
• Marked reduction in post-op mortality (1-3%) at large centers
• Continued high morbidity even at high volume centers (20-40%)
Why is pancreatic carcinoma such a fatal disease?
Vague symptoms
Lack of biomarkers
for early detection
Lack of effective systemic therapy
Basic Biology• Early, preclinical
dissemination
• Disease often systemic at presentation
What is the role of the radiologist?
Ensure protocols are optimized
Ensure consistent, reproducible imaging
Interpretation according to established guidelines
• 2014 APA/SAR Consensus Statement
• Terminology we all understand and agree upon
• What constitutes a resectable or unresectable tumor?
Categorize the lesion for our clinical colleagues
• Resectable, locally advanced, or unresectable?
Encasement with
deformity
Abutment, no
deformity
Encasement, no
deformity
• No extension to celiac, CHA, SMA, SMV-PV confluence
• No distant metastasis
• Stage I, II (T1-3, Nx, M0)
Short segment venous involvement with option for reconstruction
• GDA encasement up to HA without extension to celiac axis
• SMA abutment (<1800)
Celiac, SMA encasement (> 1800)
• Stage III (T4, Nx, M0)
T
Resectable
T
LocallyAdvanced
T
BorderlineResectable
• No extension to celiac, CHA, SMA, SMV-PV confluence
• No distant metastasis
• Stage I, II (T1-3, Nx, M0)
• Celiac, SMA encasement (> 1800)
• Stage III (T4, Nx, M0)
• Short segment venous involvement with option for reconstruction
• GDA encasement up to HA without extension to celiac axis
• SMA abutment (<1800)
NCCN criteria
• No extension to celiac, CHA, SMA, SMV-PV confluence
• No distant metastasis
• Stage I, II (T1-3, Nx, M0)
Short segment venous involvement with option for reconstruction
• GDA encasement up to HA without extension to celiac axis
• SMA abutment (<1800)
Celiac, SMA encasement (> 1800)
• Stage III (T4, Nx, M0)
T
Resectable
T
LocallyAdvanced
T
BorderlineResectable
An all too familiar story59 yo male with abdominal pain and jaundice
Lesion confined to pancreas, no vascular involvement
3.2 cm
Slide courtesy of Dr. R. B. Jeffrey, Stanford University
• R0 resection: Expired in 11 mos
• Path: Perineural invasion, macroscopic duodenal invasion
• Both are key prognostic features
What is Perineural Invasion (PNI)?
Dissemination of tumor within the potential space between the nerve
fiber and its sheath:
perineural space
Characteristic mode of spread of pancreatic cancer, rarely seen in
other GI tumors
Occurs in 70% to 100% of pancreatic cancers; reported in
lesions as small as 2 mm
N
N
Why is PNI important?
Occurs very early in the disease, leading to systemic spread
• Anoxic environment - Spread via nerve fascicles is optimal for tumor growth
• Refractory to chemo and XRT
Clinical pearl
• Affected patients often present with pain
• (As opposed to “painless jaundice”)
PNI is a major factor in the failure of surgery & mortality of pancreatic cancer
Biomarker of reduced survival
It is incredibly easy to miss on CT!
The radiologist must know where to look.
Peripancreatic Neural Plexi
The pancreatic head is richly innervated by autonomic nerve fibers coming from the celiac plexus (R and L celiac ganglia)
and superior mesenteric ganglion.
These nerve plexi surround the SMA and are interposed between the
pancreas and the artery.
The intricate neural network serves as a conduit for retrograde spread of
pancreatic cancer.
Celiac
ganglion
SMA
ganglion
Blood Supply - Pancreas
“PIPDA”
Celiac plexus
SMAganglion
Posterior inferior pancreaticoduodenal artery
4 Pathways of Perineural Invasion
PLX-1: Posterior to portal vein
Posterior to panc head and PV Celiac plexus
PLX-2: Jejunal Trunk to SMA ganglion
• Posterior to pancreas, left side of uncinate• PIPDA/Jejunal trunk = conduit
• Most common route of spread (74-90%)
Anterior
• Anteriorly along GDA to CHA plexus
Inferior
• Inferiorly into root of mesentery
Celiac
plexus
SMA
ganglion
AJR:194, March 2010
Celiac plexus in situ
• Thin, disc-like structures, <5 mm thick
• Located anterior to aorta and diaphragmatic crura, medial to adrenals
• Surround celiac trunk and root of SMA
• Thin, disc-like structures, <5 mm thick
• Located between IVC and diaphragmatic crus
Right celiac ganglion
IVC
IVC
Right celiac ganglion
Right Celiac plexus on CT
Zuo et. Al, World J Radiol 2012 February 28; 4(2): 36-43
Left Celiac plexus on CT
Panc head
Left celiac ganglion
L adrenal
• Thin, disc-like structure, <5 mm thick
• Located anterior to aorta and diaphragmatic crura, medial to adrenals
• Surround celiac trunk and root of SMA
Left celiac ganglion
L adrenal
Zuo et. Al, World J Radiol 2012 February 28; 4(2): 36-43
Perineural Plexus InvasionPosterior Pathway “PLX-1” (celiac plexus)
T
T
Coronal PNI difficult to identify
PD
Axial Posterior PNI more easily visible
Perineural Plexus LandmarksPosterior PLX-2
Normal PIPDA & Jejunal Trunk
PIPDA
JT
T
Jejunal Trunk
Perineural Plexus LandmarksPNI at Posterior PLX-2
T
PIPDA
2D thin axial
T
PIPDA
3D VR coronal
Does PNI really affect survival?
76 pts with pancreatic adenoca, all had pre-op MDCT
All 76 patients met classical resectability criteria for Whipple
All had post-op chemo
Minimum follow-up 2 yrs
49 had perineural invasion
Slide courtesy of Dr. R. B. Jeffrey, Stanford University
PNI significantly reduces survivalP=0.010
MDCT Pancreatic Protocol
To diagnose PNI: High resolution SFOV CTA to visualize 1-2 mm vessel and adjacent soft tissue infiltration
Rapid IV injection 150 ml @ 4ml/sec
Biphasic acquisition (late arterial 45 sec and venous phase 70 sec)
@ 0.625 mm collimation
Cover liver and pancreas in both phases, pelvis in PV phase
Oral contrast: 750 ml of neutral contrast right before scanning
Positive contrast can obscure small mural or ampullary lesions
20 mg buscopan IV/IM
Synoptic Reporting
Narrative ReportResectable, Borderline Resectable, or Unresectable?
OPINION:
• 5 cm low attenuation partly enhancing ill-defined solid mass head of pancreas consistent with neoplasm.
• Compression and possible invasion of splenic vein with extensive perigastric venous collateral.
• Celiac artery branches are seen to traverse the superior aspect of the mass and in particular, the common hepatic artery.
• Associated lymphadenopathy.
UNRESECTABLE
Structured vs. Narrative ReportingBeth Israel Medical Center, 120 reports (2006-2011)
A hot topic…
“Complete, accurate, and reproducible radiology reporting of disease extent is essential”
“Decision regarding resectability status should be decided in consensus at multidisciplinary meetings”
624,000 downloads of sample template between Jan-Oct 2014
Department of General Surgery
Synoptic vs Free Form CT Reporting for Periampullary Malignancies:
Can we better select operative candidates?
Jeff Hawel1, Harry Marshall3, Mike Meschino2, Esther Lau1, Heather Emmerton-Coughlin1, Catherine Yoshy3, Daniele Wiseman3,
Amol Mujoomdar3, Roberto HernandezAlejandro1, Ken Leslie1
1 Department of Surgery, Western University, London ON Canada2 Schulich School of Medicine and Dentistry, Western University, London ON Canada3 Department of Radiology, Western University, London ON Canada
Resident Research Day - April 29th, 2016
Methods• A retrospective review of our prospectively maintained PAC
database (2007-2015) was performed.• Inclusion Criteria:
i. Non-curative Whipple resection (R1) or unresectable disease at laparotomy (locally advanced or metastatic disease)
ii. Pre-operative CT with appropriate protocol for synoptic reporting performed within 90 days of OR
• Pre-operative CT scans were blindly and retrospectively re-reported by consultant radiologists, using synoptic reporting template
• Defined as resectable, borderline, or unresectable according to the NCCN guidelines
• Compared to operative findings and the original free form reports
Synoptic Imaging Reporting for Periampullary Malignancies
Results
Synoptic Imaging Reporting for Periampullary Malignancies
R1 or Unresectable/Metastatic (142)
Excluded Patients (96)Study Eligible Patients (46)
R1 Resection (14)
Locally Advanced (17)
Metastatic Disease (15)
Pre-Op Unavailable (9)
Imaging to OR > 90 days (11)
Inadequate Protocol (72)
Contraindications to CT (2)
Excluded Patients
Synoptic Imaging Reporting for Periampullary Malignancies
Exclusion Criteria # Excluded Subsequent MRI
Pre-Op Images Unavailable 7 0 0%
Original Report Unavailable 2 2 100%
Original Report Synoptic 2 2 100%
Imaging to OR > 90 days 11 9 82%
Single Phase 52 18 35%
No Pelvis 19 9 47%
Concomitant Medical Issues 2 2 100%
Technically unacceptable 1 1 100%
Total 96 43 45%
Diagnostic Accuracy
Synoptic Imaging Reporting for Periampullary Malignancies
Overall Resectability Analysis
Original Report
Resectable Borderline Unresectable Total
Staff Retrospective
Analysis
Resectable 5 1 0 6
Borderline 7 0 0 7
Unresectable 18 4 11 33
46
Agreement: 16/46 34.78%
London vs Periphery
Synoptic Imaging Reporting for Periampullary Malignancies
Resectability Analysis (London)Original Report
Resectable Borderline Unresectable Total
Staff Retrospective Analysis
Resectable 1 1 0 2
Borderline 4 0 0 4
Unresectable 9 2 10 21
27
Agreement: 11/27 41%
Resectability Analysis (Periphery)Original Report
Resectable Borderline Unresectable Total
Staff Retrospective Analysis
Resectable 4 0 0 4
Borderline 3 0 0 3
Unresectable 9 2 1 12
19
Agreement: 5/19 26%
Accuracy by NCCN Criteria
Synoptic Imaging Reporting for Periampullary Malignancies
NCCN Criteria Borderline/Unresectable Accuracy
Ascites 5/12 42%
Superior Mesenteric Artery 3/12 25%
Celiac Axis 1/5 20%
Liver Metastasis 3/16 19%
Superior Mesenteric Vein 2/21 10%
Common Hepatic Artery 0/13 0%
Arterial Variant 0/5 0%
Portal Vein 0/21 0%
Peritoneal Metastasis 0/4 0%
Surgical Outcome
Synoptic Imaging Reporting for Periampullary Malignancies
Staff Retrospective Analysis
Surgical Outcome
R1 Resection Locally Advanced Metastatic Disease
Resectable 21% 15% 7%
Borderline 43% 38% N/A
Unresectable 36% 47% 93%
79%
Surgical Outcome
Synoptic Imaging Reporting for Periampullary Malignancies
Staff Retrospective Analysis
Surgical Outcome
R1 Resection Locally Advanced Metastatic Disease
Resectable 21% 15% 7%
Borderline 43% 38% N/A
Unresectable 36% 47% 93%
93%
Multi-Disciplinary Tumor Board• NCCN Guidelines 2015:
• “Decisions about diagnostic management and resectability should involve multidisciplinary consultation…”
• Less than 10% of total non-curative (R1 and unresectable at laparotomy) cases were discussed pre-operatively at MDTB at LHSC.
Synoptic Imaging Reporting for Periampullary Malignancies
Discussion• Significant proportion of patients proceed to
resection without adequate imaging
• Synoptic reporting, coupled with expert radiologist review, better identifies and communicates CT findings to the surgeon
Synoptic Imaging Reporting for Periampullary Malignancies
Study Conclusion• Patient selection can be improved with better
communication between surgeon and radiologist
• Formal imaging review and/or MDTB should be considered for all patients before resection
Synoptic Imaging Reporting for Periampullary Malignancies
Outcomes of Retrospective Review
Establishment of Diagnostic Assessment Program (DAP)
Review of image quality to determine if repeat imaging is necessary
• We should work to eliminate this step
• Consistency of protocol is ideal
Double read CT Pancreas cases prior to issuing a report
Routine use of synoptic report for potential surgical cases
Final review at MCC for all cases unless clearly unresectable
Synoptic Report
• Used only for cases that are resectable or locally advanced– Not for clearly metastatic
tumors– Surgery not an option
• If not biopsy proven?– Must comment on surgical
criteria (vessels, CBD, ascites etc) in case lesion is malignant
– Can state histology not available
– Offer resectability status in event lesion is malignant.
Summary
Radiologists need to carefully look for features of resectability
May impact decision for surgical vs. neoadjuvant therapy
Look for perineural invasion – may be a biomarker of poor prognosis
Pancreatic adenocarcinoma – still a bad news story?
Eliminates repeat imaging and ensuing delays
Standardization of protocols
Report should contain all information needed for treatment planning
Potentially resectable cases should be discussed at MCC
Dialogue between radiology/surgery essential!
Synoptic Reporting